2026 · 2nd Quarter (Apr 1 - June 30)

RARE DISEASE COMPANY COALITION

Filed by RARE DISEASE COMPANY COALITION.

Open official filing

Source-reported fields

Filing overview

Type: 2nd Quarter - Report
Posted: Jul 16, 2026
Income: Not reported
Expenses: $70,000.00
Registrant: RARE DISEASE COMPANY COALITION
Client: RARE DISEASE COMPANY COALITION
Filing UUID: 4c95c921-f1a5-4076-a184-f967a6518e53
Termination date: Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

PHA · Pharmacy

HR 1 / Public Law - ORPHAN Cures Act HR 1414 - Camerons Law HR 7148 / Public Law 119-75 - PRV Reauthorization CMS-5545-P - Global Benchmark for Efficient Drug Pricing (GLOBE) CMS-5546-P - Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Proclamation 11020 - Exemption for Orphan Drugs from 232 Pharmaceutical Tariffs Rare Disease Innovation Issues

Literal federal measure citations: HR 1, HR 1414, HR 7148

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.